Merck’s Ebola Vaccine Ervebo Prequalified by WHO

(Bloomberg) -- The World Health Organization prequalified an ebola vaccine for the first time -- Merck’s vaccine, Ervebo -- which speeds up licensing, access and roll-out in high-risk countries.

• Prequalification means that vaccine meets WHO standards for quality, safety and efficacy
• Vaccine can be procured by UN agencies and Gavi, the vaccine alliance, for at-risk countries
• Decision comes less than 48 hours after European Commission decision to grant a conditional marketing authorization for the vaccine
• Ervbo shown to be effective in protecting people from the Ebola Zaire virus
• Licensed doses will only be available mid-2020
• NOTE: Nov. 11 Merck & Co.’s Ebola Vaccine Ervebo Gets EC Approval

To contact the reporter on this story: Madison Park in San Francisco at mpark197@bloomberg.net

To contact the editor responsible for this story: Sebastian Tong at stong41@bloomberg.net

©2019 Bloomberg L.P.